查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1790402

美国注意力不足过动症市场规模、份额和趋势分析报告：按药物类型、人口统计、分销管道和细分市场预测，2025 年至 2033 年

U.S. Attention Deficit Hyperactivity Disorder Market Size, Share, & Trends Analysis Report By Drug Type (Stimulants, Non-stimulants), By Demographics (Children, Adults), By Distribution Channel, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国注意力不足过动症市场摘要

美国注意力不足过动症市场规模预计在 2024 年为 103.1 亿美元，预计到 2033 年将达到 138.8 亿美元，2025 年至 2033 年的复合年增长率为 3.3%。该市场的主要驱动力是诊断病例的持续增加，这得益于诊断标准的扩大、公众意识的提高以及初级保健筛检一致性的提高。

注意力不足过动症(ADHD) 仍然是美国最常见的神经发育障碍之一，影响着临床实践和公共卫生倡议。 2020-2022 年全国健康访问调查报告显示，11.3% 的 5-17 岁美国儿童曾被诊断为 ADHD。男孩（14.5%）被诊断的可能性大约是女孩（8.0%）的两倍。成年人也观察到了类似的趋势，18-44 岁族群中 ADHD 的终生盛行率估计约为 8.1%。

在学校筛检计画和放鬆管制措施的推动下，看护者和教育工作者的意识不断增强，确诊者人数正在进一步扩大。治疗方案的创新也是美国注意力不足过动症)产业成长的主要驱动力。儘管哌甲酯和安非他命非他明等兴奋剂仍占据处方药的主导地位，但近期的进展凸显了市场向非兴奋剂和数位疗法的转变。 2023年12月，FDA 将首个基于游戏的数位疗法 EndeavorRx 的适应症扩展至13-17岁的青少年，此前关键的 STARS-ADHD 试验数据显示，经 ToVa 评估，该疗法显着改善了患者的注意力（p<0.0001）。

医疗服务提供和付款人政策的变化持续影响着市场动态。远端医疗的广泛应用因 COVID-19 疫情而加速，透过促进更频繁的后续观察和剂量调整，正在减少持续照护的障碍。此外，更新后的保险覆盖指南现在允许将数位和行为疗法与药物治疗一起纳入承保范围。特别是随着人们越来越关注焦虑症和学习障碍等合併症，将行为疗法与药物管理相结合的综合护理模式在儿科和青少年医疗保健网络中变得越来越突出。 2025 年 1 月，Supernus Pharmaceuticals 获得了 FDA 对 Qelbree 的标籤更新，增加了针对哺乳妇女的新动态数据和资讯。

过动症 (ADHD) 领域的併购交易相对谨慎，主要涉及寻求扩大治疗和数位健康产品组合的专业製药公司。 2024 年 9 月，Collegium Pharmaceuticals 收购了 Ironshore Therapeutics。透过此次收购，Collegium Pharmaceuticals 扩大了其在神经病学领域，尤其是过动症 (ADHD) 市场的影响力，并将 ADHD 治疗药物 Jornay PM 纳入其产品组合。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国注意力不足过动症市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国注意力不足过动症（ADHD）市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
  • 美国注意力不足过动症（ADHD）市场：通路分析

第四章美国注意力不足过动症市场：药物类型估计与趋势分析

  • 药品类型细分仪表板
  • 美国注意力不足过动症（ADHD）市场：按药物类型进行的变化分析
  • 美国注意力不足过动症(ADHD) 市场规模及趋势分析（依药物类型），2021 年至 2033 年
  • 兴奋剂
    • 安非他命
    • 哌甲酯
    • Lisdexamfetamine
    • 右哌甲酯
  • 无刺激性
    • 阿托西汀
    • 胍法辛
    • 可乐定
    • 其他的

第五章美国注意力不足过动症市场：人口统计估计与趋势分析

  • 人口统计细分仪表板
  • 美国注意力不足过动症（ADHD）市场：人口变化分析
  • 美国注意力不足过动症(ADHD) 市场规模及趋势分析（依人口统计），2021 年至 2033 年
  • 孩子
  • 成人

第六章美国注意力不足过动症市场：通路评估与趋势分析

  • 分销通路细分仪表板
  • 美国注意力不足过动症（ADHD）市场：分销管道差异分析
  • 美国注意力不足过动症(ADHD) 市场规模及趋势分析（按分销管道），2021 年至 2033 年
  • 零售药局
  • 医院药房

第七章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • Key company heat map analysis, 2024
  • 公司简介
    • Lilly.
    • Pfizer Inc.
    • Johnson &Johnson
    • Lupin Pharmaceuticals, Inc.
    • Novartis Pharmaceuticals Corporation
    • Takeda Pharmaceutical Company Limited.
    • Mallinckrodt.
    • PURDUE PHARMA LP
    • NEOS THERAPEUTICS, INC.
    • Supernus Pharmaceuticals, Inc.
Product Code: GVR-4-68040-665-9

U.S. Attention Deficit Hyperactivity Disorder Market Summary

The U.S. attention deficit hyperactivity disorder market size was estimated at USD 10.31 billion in 2024 and is projected to reach USD 13.88 billion by 2033, growing at a CAGR of 3.3% from 2025 to 2033. The market is primarily driven by a continuous increase in diagnosed cases, supported by expanded diagnostic criteria, greater public awareness, and more consistent screening in primary care settings.

Attention Deficit Hyperactivity Disorder (ADHD) remains one of the most commonly diagnosed neurodevelopmental disorders in the U.S., shaping clinical practice and public health initiatives. A 2020-2022 National Health Interview Survey reported that 11.3% of U.S. children aged 5 to 17 have been diagnosed with ADHD at some point. Boys (14.5%) are nearly twice as likely as girls (8.0%) to receive a diagnosis. Similar trends are seen in adults, with lifetime ADHD prevalence estimated at around 8.1% among those aged 18 to 44.

Growing awareness among caregivers and educators, driven by school screening programs and destigmatization efforts, is further expanding the pool of patients being identified. Innovation in treatment options is another major driver of growth of the U.S. attention deficit hyperactivity disorder industry. Although stimulant medications such as methylphenidate and amphetamines continue to dominate prescriptions, recent advances highlight the market's shift toward non-stimulant and digital therapies. In December 2023, the FDA expanded the indication for EndeavorRx, the first game-based digital therapeutic, to include adolescents aged 13 to 17, following pivotal STARS-ADHD trial data showing significant attention improvements on TOVA assessments (p < 0.0001).

Changes in care delivery and payer policies continue to influence market dynamics. The widespread adoption of telehealth, accelerated by the COVID-19 pandemic, has reduced barriers to ongoing treatment by facilitating more frequent follow-ups and dose adjustments. In addition, updated insurance coverage guidelines now commonly reimburse digital and behavioral therapies alongside medication. Integrated care models that combine behavioral therapy with medication management within pediatric and adolescent health networks are becoming increasingly prominent, especially as comorbid conditions such as anxiety and learning disorders receive greater attention. In January 2025, Supernus Pharmaceuticals obtained an FDA label update for Qelbree, adding new pharmacodynamic data and information on breastfeeding women.

M&A activity in the ADHD segment is relatively selective, primarily involving specialty pharmaceutical companies aiming to broaden their therapeutic or digital health portfolios. In September 2024, Collegium Pharmaceutical acquired Ironshore Therapeutics. The deal expanded Collegium's reach in the neurology sector, specifically in the ADHD market, and added Jornay PM, a stimulant to treat ADHD, to its portfolio.

U.S. Attention Deficit Hyperactivity Disorder Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. attention deficit hyperactivity disorder market report based on drug type, demographics, and distribution channel:

  • Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Stimulants
  • Amphetamine
  • Methylphenidate
  • Lisdexamfetamine
  • Dexmethylphenidate
  • Non-stimulants
  • Atomoxetine
  • Guanfacine
  • Clonidine
  • Others
  • Demographics Outlook (Revenue, USD Million, 2021 - 2033)
  • Children
  • Adults
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Retail Pharmacy
  • Hospital Pharmacy

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Type
    • 1.2.2. Demographics
    • 1.2.3. Distribution Channel
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Type Outlook
    • 2.2.2. Demographics Outlook
    • 2.2.3. Distribution Channel Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Attention Deficit Hyperactivity Disorder Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. U.S. Attention Deficit Hyperactivity Disorder Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political Landscape
      • 3.3.2.2. Technological Landscape
      • 3.3.2.3. Economic Landscape
  • 3.4. U.S. Attention Deficit Hyperactivity Disorder Market: Pipeline Analysis

Chapter 4. U.S. Attention Deficit Hyperactivity Disorder Market: Drug Type Estimates & Trend Analysis

  • 4.1. Drug Type Segment Dashboard
  • 4.2. U.S. Attention Deficit Hyperactivity Disorder Market: Drug Type Movement Analysis
  • 4.3. U.S. Attention Deficit Hyperactivity Disorder Market Size & Trend Analysis, by Drug Type, 2021 - 2033 (USD Million)
  • 4.4. Stimulants
    • 4.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 4.4.2. Amphetamine
      • 4.4.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 4.4.3. Methylphenidate
      • 4.4.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 4.4.4. Lisdexamfetamine
      • 4.4.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 4.4.5. Dexmethylphenidate
      • 4.4.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.5. Non-stimulants
    • 4.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 4.5.2. Atomoxetine
      • 4.5.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 4.5.3. Guanfacine
      • 4.5.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 4.5.4. Clonidine
      • 4.5.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 4.5.5. Others
      • 4.5.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 5. U.S. Attention Deficit Hyperactivity Disorder Market: Demographics Estimates & Trend Analysis

  • 5.1. Demographics Segment Dashboard
  • 5.2. U.S. Attention Deficit Hyperactivity Disorder Market: Demographics Movement Analysis
  • 5.3. U.S. Attention Deficit Hyperactivity Disorder Market Size & Trend Analysis, by Demographics, 2021 - 2033 (USD Million)
  • 5.4. Children
    • 5.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 5.5. Adults
    • 5.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 6. U.S. Attention Deficit Hyperactivity Disorder Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Distribution Channel Segment Dashboard
  • 6.2. U.S. Attention Deficit Hyperactivity Disorder Market: Distribution Channel Movement Analysis
  • 6.3. U.S. Attention Deficit Hyperactivity Disorder Market Size & Trend Analysis, by Distribution Channel, 2021 - 2033 (USD Million)
  • 6.4. Retail Pharmacy
    • 6.4.1. Market Estimates and Forecasts 2021 - 2033 (USD million)
  • 6.5. Hospital Pharmacy
    • 6.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key company heat map analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Lilly.
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Pfizer Inc.
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Johnson & Johnson
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Lupin Pharmaceuticals, Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Novartis Pharmaceuticals Corporation
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Takeda Pharmaceutical Company Limited.
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Mallinckrodt.
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. PURDUE PHARMA L.P.
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. NEOS THERAPEUTICS, INC.
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Supernus Pharmaceuticals, Inc.
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. attention deficit hyperactivity disorder market, by drug type, 2021 - 2033 (USD Million)
  • Table 3 U.S. attention deficit hyperactivity disorder market, by demographics, 2021 - 2033 (USD Million)
  • Table 4 U.S. attention deficit hyperactivity disorder market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. attention deficit hyperactivity disorder market: market outlook
  • Fig. 10 U.S. androgenetic alopecia competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. attention deficit hyperactivity disorder market driver impact
  • Fig. 16 U.S. attention deficit hyperactivity disorder market restraint impact
  • Fig. 17 U.S. Attention deficit hyperactivity disorder market strategic initiatives analysis
  • Fig. 18 U.S. attention deficit hyperactivity disorder market: drug type movement analysis
  • Fig. 19 U.S. attention deficit hyperactivity disorder market: drug type outlook and key takeaways
  • Fig. 20 Stimulants market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 Amphetamine estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Methylphenidate estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Lisdexamfetamine estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Dexmethylphenidate estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Non-stimulants market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Atomoxetine estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Guanfacine estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 Clonidine estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Others estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. attention deficit hyperactivity disorder market: demographics movement analysis
  • Fig. 31 U.S. attention deficit hyperactivity disorder market: demographics outlook and key takeaways
  • Fig. 32 Children (2-17 years) estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 33 Adults estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 Others estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 35 U.S. attention deficit hyperactivity disorder market: distribution channel movement analysis
  • Fig. 36 U.S. attention deficit hyperactivity disorder market: distribution channel outlook and key takeaways
  • Fig. 37 Hospital pharmacy estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 38 Retail pharmacy estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 39 Others estimates and forecast, 2021 - 2033 (USD Million)